Melanoma-associated antigen family A member 3 (MAGE-A3)

Melanoma-associated antigen family A member 3 (**MAGE-A3**) is a tumor-associated protein belonging to the type I **MAGE** gene family. It is normally expressed only in reproductive tissues like the testis but becomes aberrantly re-expressed in various cancers—including melanoma—where its presence correlates with poor prognosis and increased metastasis risk. Functionally, **MAGE-A3** acts as an activator of RING-type zinc finger-containing E3 ubiquitin-protein ligases such as TRIM28, modulating their activity toward substrates involved in apoptosis regulation and autophagy repression. This makes it both an oncogenic driver and an attractive therapeutic target. Structurally, **MAGE-A proteins** contain tandem winged helix domains that mediate effector binding; small molecules can bind at dimer interfaces or allosteric sites affecting function or stability. The selective expression pattern has led to development efforts around immunotherapies (e.g., vaccines) and targeted protein degraders (PROTACs), aiming either at direct elimination or enhanced immune recognition by increasing peptide presentation on tumor cells. Because its normal tissue distribution is highly restricted while being widely present across multiple tumor types, **MAGE-A3** serves both as a diagnostic/prognostic biomarker and a promising candidate for precision oncology interventions—though safety concerns regarding off-target effects remain under investigation.[1][2][4][5][6]

Other names

MAGEA3Melanoma antigen gene-A3MAGA3_HUMAN (UniProt identifier)Melanoma-associated antigen 3[7]

Small-molecule degraders (PROTACs) recruit the VHL E3 ligase to induce proteasomal degradation of MAGE-A3 in cancer cells expressing this protein.[2] * Immunotherapeutic approaches target peptides derived from MAGE-A3 presented on tumor cells to stimulate cytotoxic T-cell responses.[1]